Dossier
Summit Therapeutics
Coverage of Summit Therapeutics in the Nexus archive.
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug developed by Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial conducted in China, according to recently released data.
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
Ivonescimab, developed by Akeso Therapeutics and Summit Therapeutics, reduced the risk of death by 34% in patients with squamous non-small cell lung cancer compared to standard treatment in a China-based clinical trial. Results were presented at the American Society of Clinical Oncology meeting and published in The Lancet, with Summit’s co-CEO highlighting the drug’s potential business value.